My research group is dedicated to the development of novel radiopharmaceuticals for diagnostic and therapeutic applications, and, aiding clinical translation of these novel radiopharmaceuticals to the clinic.
Tumor Targeting and Cell-trafficking Studies of 131I/124I]-FIAU-labeled Genetically Modified Antigen-specific Lymphocytes
Donor T cells are reactive against and effective in adoptive immunotherapy of Epstein-Barr virus (EBV) lymphomas, which develop in some leukemia patients after marrow transplantation. Such T cells have been genetically modified by incorporation of a replication-incompetent vector (NIT) for an inactive mutant nerve growth factor receptor (LNGFR) as an immunoselectable surface marker and a herpes simplex virus thymidine kinase gene (HSV-TK), rendering the cells sensitive to ganciclovir.
Tumor multiple drug resistance (MDR) is defined as the property of cancer cells to resist the action of a large variety of chemically and functionally unrelated substances, including but not limited to chemotherapeutic drugs.
Monoclonal antibodies and antibody fragments raised against a variety of tumor-specific and tumor-associated epitopes have been labeled with a variety of radioisotopes for tumor imaging by single-photon emission computed tomography (SPECT) and, more recently, for positron emission tomography (PET) and internal radionuclide therapy.